Booting Earth Optimization System
Thank you for your patience. Your civilization is very important to us.
Tofacitinib
Treatment for Inflammatory bowel disease
Typical Dosage: 5-10 mg twice daily
Effectiveness
72%
Safety Score
48%
Clinical Trials
40
Participants
8K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
48
DangerousModerateSafe
Treatment Details
Dosage Range
5-10 mg twice daily
Time to Effect
2-8 weeks
Treatment Duration
lifetime
Evidence Quality
HIGHNumber Needed to Treat (NNT)
6(Treat 6 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
40(Treat 40 patients to see 1 additional serious adverse event)
Confidence Score
85%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$40,000
Monitoring:$4,000
Side Effect Mgmt:$2,500
Total Annual:$46,500
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
POORICER
$250,000/QALY
QALYs Gained
0.25
Outcome-Based Costs
Cost per Responder
$84,545
Cost per Remission
$258,333
Comparison vs Azathioprine
Cost Difference
+$45,000/year
More expensive
QALY Difference
+0.10 QALYs
Better outcomes
Dominance
No dominance
Tofacitinib Outcomes
for Inflammatory bowel disease
Efficacy Outcomes
Overall Effectiveness
+72%
Response Rate
+55%
Remission Rate
+18%
Common Side Effects
Nasopharyngitis
+15%
Herpes Zoster
+7%
Upper respiratory tract infection
+10%
Serious infections
+2.5%
MACE/Malignancy
+1.5%
Sources:
WARNING: LIMITED TRIALS AVAILABLE
You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!
Active Clinical Trials
9 active trials recruiting for Tofacitinib in Inflammatory bowel disease
TOFACITINIB vs TOFACITINIB WITH MESALAMINE IN ULCERATIVE COLITIS
NCT06625450NOT YET RECRUITINGPHASE4
75 participants
INTERVENTIONAL
Started: Oct 1, 2024
Evaluation of Oral Tofacitinib in Children Aged 2 to 17 Years Old Suffering From Moderate to Severe Ulcerative Colitis
NCT04624230ACTIVE NOT RECRUITINGPHASE3
118 participants
INTERVENTIONAL
Los Angeles, United States +72 more
Started: Aug 12, 2021
A Prospective Cohort Study Evaluating the Efficacy and Safety of Guselkumab (GUS) With JAK Inhibitors in Patients With Difficult-To-Treat Inflammatory Bowel Disease (IBD)
NCT07487311RECRUITING
80 participants
OBSERVATIONAL
Hangzhou, China
Started: Jan 7, 2026
Observational Study To Assess The Effectiveness and Treatment Adherence Of Tofacitinib of Ulcerative Colitis In Clinical Practice In Sweden
NCT04338204RECRUITING
120 participants
OBSERVATIONAL
Alingsås, Sweden +16 more
Started: Sep 14, 2020
A Study of Vedolizumab With Tofacitinib in Adults With Ulcerative Colitis (UC)
NCT06095128RECRUITINGPHASE4
65 participants
INTERVENTIONAL
Dothan, United States +48 more
Started: Jun 12, 2024
Tofacitinib Versus Cyclosporine for Steroid Refractory Acute Severe Ulcerative Colitis
NCT05112263NOT YET RECRUITINGNA
96 participants
INTERVENTIONAL
Started: Jul 1, 2023
Prediction Model for Response to Biologics and Small Molecular Agent for UC
NCT05186623RECRUITING
300 participants
OBSERVATIONAL
Seoul, South Korea
Started: Feb 5, 2022
COMPARE - Pediatric Inflammatory Bowel Disease (PIBD)
NCT07198113RECRUITING
1.1K participants
OBSERVATIONAL
Chapel Hill, United States +3 more
Started: Nov 1, 2025
Effect of Tofacitinib on Coagulation and Platelet Function, and Its Role in Thromboembolic Events
NCT05313620RECRUITINGPHASE4
30 participants
INTERVENTIONAL
Madrid, Spain
Started: Apr 1, 2022
Completed Clinical Trials
7 completed trials for Tofacitinib in Inflammatory bowel disease
Safety and Efficacy of Tofacitinib for Chronic Granulomatous Disease With Inflammatory Complications
NCT05104723COMPLETEDPHASE1, PHASE2
10 participants
INTERVENTIONAL
Bethesda, United States
Started: Aug 12, 2022
Identification of Predictive Biomarkers for Response to Biologic Therapies and Tofacitinib in Inflammatory Bowel Disease
NCT03885713COMPLETEDPHASE4
180 participants
INTERVENTIONAL
Alicante, Spain +20 more
Started: Sep 10, 2019
Tofacitinib in Adult Patients With Moderate to Severe Ulcerative Colitis
NCT04424303COMPLETED
152 participants
OBSERVATIONAL
Amiens, France +37 more
Started: Dec 4, 2020
Retrospective Observational Comparison Study Between Ustekinumab and Tofacitinib as Third Line Therapy in a Multicenter Cohort of Patients With Refractory Ulcerative Colitis.
NCT05728008COMPLETED
100 participants
OBSERVATIONAL
Milan, Italy
Started: Apr 5, 2022
A Study Evaluating The Efficacy And Safety Of CP-690,550 In Patients With Moderate To Severe Ulcerative Colitis
NCT01465763COMPLETEDPHASE3
614 participants
INTERVENTIONAL
Mobile, United States +177 more
Started: Apr 1, 2012
A Study To Evaluate Both The Efficacy and Safety Profile of CP-690,550 In Patients With Moderately to Severely Active Ulcerative Colitis
NCT01458951COMPLETEDPHASE3
547 participants
INTERVENTIONAL
Tucson, United States +181 more
Started: Jun 1, 2012
The Safety And Efficacy Of Maintenance Therapy With CP-690,550
NCT01393899COMPLETEDPHASE2
180 participants
INTERVENTIONAL
Anaheim, United States +90 more
Started: Mar 1, 2012
Showing 20 of 41 total trials